Konsolideringen indenfor kræftområdet forsætter i stor stil:
"Drugmaker AbbVie Inc (ABBV.N) said it will buy Pharmacyclics Inc (PCYC.O), the maker of blockbuster cancer drug Imbruvica, for about $21 billion to broaden its oncology drugs pipeline.
Related Stories
The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago-based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales".
http://finance.yahoo.com/news/abbvie-buy-cancer-drug-maker-050113563.html
"Drugmaker AbbVie Inc (ABBV.N) said it will buy Pharmacyclics Inc (PCYC.O), the maker of blockbuster cancer drug Imbruvica, for about $21 billion to broaden its oncology drugs pipeline.
Related Stories
The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago-based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales".
http://finance.yahoo.com/news/abbvie-buy-cancer-drug-maker-050113563.html
